Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5-6
|
| pubmed:dateCreated |
1997-6-12
|
| pubmed:abstractText |
Age has proved to be an important prognostic factor in patients with advanced non-Hodgkin lymphoma (NHL) and these patients require intensive and extensive therapy. Dose-reduction and therapy attenuation have reduced treatment-related toxicity, but have also decreased therapeutic efficacy. Between January 1990 and December 1992, 41 previously untreated patients, 65 years with stage 2-4 intermediate- or high-grade NHL were treated with a new therapeutic scheme which included Mitoxantrone, Etoposide, Cyclophosphamide and Prednisone (MiCEP). Twenty-eight patients achieved a complete remission, ten patients partial remission (overall response rate of 93%) and two cases were resistant. The overall survival was 66% with a median follow-up of 24 months from diagnosis: three patients relapsed after a median period of 7 months. The relapse-free survival was 92% after a median follow-up of 18 months. Blood and other organ toxicity was acceptable and 12% of patients experienced a grade 4 (WHO) neutropenia. In conclusion, MiCEP was effective in inducing a good remission rate with moderate toxic effects in elderly patients with intermediate- or high-grade NHL and appears to be a useful combination to use in this group of patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1042-8194
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
475-80
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8833406-Aged,
pubmed-meshheading:8833406-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8833406-Cyclophosphamide,
pubmed-meshheading:8833406-Disease-Free Survival,
pubmed-meshheading:8833406-Etoposide,
pubmed-meshheading:8833406-Feasibility Studies,
pubmed-meshheading:8833406-Female,
pubmed-meshheading:8833406-Gastrointestinal Diseases,
pubmed-meshheading:8833406-Hematologic Diseases,
pubmed-meshheading:8833406-Humans,
pubmed-meshheading:8833406-Life Tables,
pubmed-meshheading:8833406-Lymphoma, Non-Hodgkin,
pubmed-meshheading:8833406-Male,
pubmed-meshheading:8833406-Mitoxantrone,
pubmed-meshheading:8833406-Prednisone,
pubmed-meshheading:8833406-Remission Induction,
pubmed-meshheading:8833406-Survival Analysis,
pubmed-meshheading:8833406-Treatment Outcome
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
|
| pubmed:affiliation |
Cattedra e Divisione di Ematolgia e Istituto di Anatomia e Istologia Patologica, Universita degli Studi e Ospedale di Careggi, Firenze, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|